Supplementary Figures S1--S13 Lange PF, Huesgen PF, Nguyen K, Overall CM Annotating N termini for the Human Proteome Project:
Nα termini and N--acetylation status differentiate stable cleaved protein species from degradation remnants in the human erythrocyte proteome Supplementary Figure S6 . Evidence for missing protein cancer/testis antigen 75 (Q6PK30). Representative spectra out of a total of 17 spectra supporting the peptide sequence ECPSLSALR. E CPSLSALR, MH+ 1066.5820, m/z 533.7946 File: 120212_RBC6_ST_Fr12.3778.3778.2, Scan: 3778, Precursor m/z: 533.7929 Nα termini and N--acetylation status differentiate stable cleaved protein species from degradation remnants in the human erythrocyte proteome Supplementary Figure S7 . Evidence for missing protein intercellular adhesion molecule 4 (Q14773). Representative spectra out of a total of ten spectra supporting peptide sequences LNLDGLVVR and VIYSESLER. Nα termini and N--acetylation status differentiate stable cleaved protein species from degradation remnants in the human erythrocyte proteome Supplementary Figure S8 . Evidence for missing protein leucine--rich repeat transmembrane neuronal protein 1 (Q86UE6). Representative spectra out of a total of 87 spectra supporting peptide sequence LSLRYNSLSE. Supplementary Figures S1--S13 Lange PF, Huesgen PF, Nguyen K, Overall CM Annotating N termini for the Human Proteome Project:
Nα termini and N--acetylation status differentiate stable cleaved protein species from degradation remnants in the human erythrocyte proteome Supplementary  Figure  S10 . Evidence for missing protein protein FAM43A (Q8N2R8). Spectra supporting peptide sequence LEQELQEEEE. 
Supplementary
Figures S1--S13 Lange PF, Huesgen PF, Nguyen K, Overall CM Annotating N termini for the Human Proteome Project:
Nα termini and N--acetylation status differentiate stable cleaved protein species from degradation remnants in the human erythrocyte proteome Supplemental Figure S12 . Sequence determinants of cotranslational Met processing and N--terminal acetylation in human erythrocytes. Sequence logos representing A) 111 N termini with intact Met at position 1 of the gene--encoded protein sequence (--.Met1); B) 29 N termini with intact Met, mapping to positions >2 of the gene--encoded protein sequence, suggesting alternative translation start sites (X.Met); C) 304 N termini starting at position 2 after co--translational Met processing (Met1.X); D) 22 N termini with intact Met, mapping to positions >2 of the gene--encoded protein sequence, suggesting Met processing at alternative translation start sites (Met.X); E) 126 acetylated N termini starting with Met (combined canonical and alternative start sites, --.acMet); F) 14 free N termini starting with Met (combined canonical and alternative start sites, --.freeMet); G) 289 N termini acetylated after Met processing (combined canonical and alternative start sites, Met.acX); H) 36 free Met--processed N termini (combined canonical and alternative start sites, Met.freeX). Figure S5 . Sequence determinants of cotranslational Met processing and N-terminal acetylation in human erythrocytes. Sequence logos representing A) 111 N termini with intact Met at position 1 of the gene-encoded protein sequence (-.Met1); B) 29 N termini with intact Met, mapping to positions >2 of the gene-encoded protein sequence, suggesting alternative translation start sites (X.Met); C) 304 N termini starting at position 2 after co-translational Met processing (Met1.X); D) 22 N termini with intact Met, mapping to positions >2 of the gene-encoded protein sequence, suggesting Met processing at alternative translation start sites (Met.X); E) 126 acetylated N termini with intact start Met (-.acMet1); F) 14 free N termini with intact initiating Met (-.freeMet1); G) 289 N termini acetylated after Met processing (combined canonical and alternative start sites, Met.acX); H) 36 free Metprocessed N termini (combined canonical and alternative start sites, Met.freeX).
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